“Demand for GLP-1 medications is at an all-time high, but too many Americans still face barriers accessing them,” GoodRx CEO and President Wendy Barnes said in a statement.

“While Ozempic is well covered in the US, let’s not forget that there are some patients who pay out-of-pocket for this vital medicine,” Dave Moore, executive vice president, of Novo Nordisk’s U.S. op...

The move comes as President Trump is pressuring drugmakers to lower drug costs.